1. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial
- Author
-
Jorge A. Marrero, Josep M. Llovet, Antonio Craxì, Armando Santoro, Guido Gerken, Michael Shan, Michel Beaugrand, M. Moscovici, Camillo Porta, Jean-Luc Raoul, Luigi Bolondi, Jordi Bruix, D. Voliotis, Morris Sherman, Vincenzo Mazzaferro, Angelo Sangiovanni, Peter R. Galle, Andrea Nadel, Bruix, J, Raoul, JL, Sherman, M, Mazzaferro, V, Bolondi, L, Craxi, A, Galle, PR, Santoro, A, Beaugrand, M, Sangiovanni, A, Porta, C, Gerken, G, Marrero, JA, Nadel, A, Shan, M, Moscovici, M, Voliotis, D, Llovet, JM, Bruix, Jordi, Raoul, Jean-Luc, Sherman, Morri, Mazzaferro, Vincenzo, Bolondi, Luigi, Craxi, Antonio, Galle, Peter R, Santoro, Armando, Beaugrand, Michel, Sangiovanni, Angelo, Porta, Camillo, Gerken, Guido, Marrero, Jorge A, Nadel, Andrea, Shan, Michael, Moscovici, Mariu, Voliotis, Dimitri, and Llovet, Josep M
- Subjects
Oncology ,Male ,Time Factors ,Medizin ,Kaplan-Meier Estimate ,Severity of Illness Index ,law.invention ,Antineoplastic Agent ,0302 clinical medicine ,Randomized controlled trial ,law ,Medicine ,Overall survival ,Disease control rate ,Fatigue ,Time to progression ,Hazard ratio ,Liver Neoplasms ,hepatocellular carcinoma ,Middle Aged ,Sorafenib ,3. Good health ,Tumor Burden ,Alcoholism ,Subset analyses ,Liver Neoplasm ,030220 oncology & carcinogenesis ,Hepatocellular carcinoma ,Disease Progression ,030211 gastroenterology & hepatology ,Female ,Hand-Foot Syndrome ,Human ,medicine.drug ,Phenylurea Compound ,Diarrhea ,Niacinamide ,medicine.medical_specialty ,Carcinoma, Hepatocellular ,Time Factor ,Antineoplastic Agents ,Placebo ,03 medical and health sciences ,Hepatitis B, Chronic ,Internal medicine ,Humans ,neoplasms ,Aged ,Neoplasm Staging ,Proportional Hazards Models ,Performance status ,Hepatology ,business.industry ,Phenylurea Compounds ,Hepatitis C, Chronic ,medicine.disease ,digestive system diseases ,Surgery ,Clinical trial ,Proportional Hazards Model ,Liver function ,business - Abstract
BACKGROUND & AIMS: The Sorafenib Hepatocellular Carcinoma (HCC) Assessment Randomized Protocol (SHARP) trial demonstrated that sorafenib improves overall survival and is safe for patients with advanced HCC. In this trial, 602 patients with well-preserved liver function (>95% Child-Pugh A) were randomized to receive either sorafenib 400mg or matching placebo orally b.i.d. on a continuous basis. Because HCC is a heterogeneous disease, baseline patient characteristics may affect individual responses to treatment. In a comprehensive series of exploratory subgroup analyses, data from the SHARP trial were analyzed to discern if baseline patient characteristics influenced the efficacy and safety of sorafenib. METHODS: Five subgroup domains were assessed: disease etiology, tumor burden, performance status, tumor stage, and prior therapy. Overall survival (OS), time to progression (TTP), disease control rate (DCR), and safety were assessed for subgroups within each domain. RESULTS: Subgroup analyses showed that sorafenib consistently improved median OS compared with placebo, as reflected by hazard ratios (HRs) of 0.50-0.85, similar to the complete cohort (HR=0.69). Sorafenib also consistently improved median TTP (HR, 0.40-0.64), except in HBV-positive patients (HR, 1.03), and DCR. Results are limited by small patient numbers in some subsets. The most common grade 3/4 adverse events included diarrhea, hand-foot skin reaction, and fatigue; the incidence of which did not differ appreciably among subgroups. CONCLUSIONS: These exploratory subgroup analyses showed that sorafenib consistently improved median OS and DCR compared with placebo in patients with advanced HCC, irrespective of disease etiology, baseline tumor burden, performance status, tumor stage, and prior therapy.
- Published
- 2012